|
Jun 21
|
Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
|
Jun 20
|
Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
|
Jun 18
|
Mustang (MBIO) Soars 477% on Data From Rare Blood Cancer Study
|
|
Jun 17
|
Top Midday Gainers
|
|
Jun 17
|
Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy
|
|
May 2
|
Mustang Bio Announces Closing of $4 Million Public Offering
|
|
Apr 30
|
Mustang Bio Announces Pricing of $4 Million Public Offering
|
|
Mar 28
|
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases
|
|
Mar 11
|
Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
|
|
Mar 7
|
Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma
|
|
Jan 11
|
Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference
|
|
Dec 11
|
Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting
|
|
Jul 31
|
Mustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) Biosciences
|
|
May 26
|
Wall Street Analysts Believe Mustang Bio, Inc. (MBIO) Could Rally 711.55%: Here's is How to Trade
|